Does pulsatile administration of glucagon-like peptide-1 (GLP-1) when compared to continuous infusion have a greater effect on insulin secretion and blood glucose lowering in healthy humans?

The effects of pulsatile, when compared to continuous, infusion of glucagon-like peptide-1 on insulin secretion and blood glucose in healthy humans

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12612001040853

Enrollment

Registered

2012-09-28

Start date

2013-04-05

Completion date

2013-08-16

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The purpose of this study is to determine the optimum administration method of glucagon-like peptide-1 (GLP-1), by evaluating whether pulsatile administration of GLP-1 causes greater insulin secretion and glucose lowering when compared with continuous administration.

Interventions

Intervention: 1ml bolus of glucagon-like peptide-1 (GLP-1)at 3.6 pmol/kg every 6 minutes and a continuous infusion of 0.9% isotonic saline (1 ml/min) both intravenously for 120min. Subjects will be studied on three occasions sperated by a minimum of 3 days.

Study design

Allocation

Randomised controlled trial

Intervention model

Crossover

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

18 Years to 35 Years

Healthy volunteers

Yes

Inclusion criteria

Healthy volunteers able to give informed consent

Exclusion criteria

Inability to give informed consent History of diabetes Women who are pregnant or lactating History of pancreatitis Haemoglobin <125g/L for women and <135g/L for men Glycated haemoglobin (HbA1c) >6.0 % Ferritin levels for women <10microgram/L and <20microgram/L for men Estimated glomerular filtration rate < 60ml/min Impaired liver function (ALT: >55 U/L; Albumin: <34g/l; ALP: >110 U/L; Bilirubin: >25 micro mol; GGT: >80U/L) Blood donation within the previous 12 weeks BMI <18.5 or >30kgm^2 Taking blood-glucose lowering drugs

Outcome results